Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Price Target at $25.46

Kura Oncology, Inc. (NASDAQ:KURA) has received a consensus recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $25.4615.

Several equities research analysts have recently issued reports on KURA shares. Lake Street Capital assumed coverage on Kura Oncology in a research note on Tuesday, April 14th. They issued a “buy” rating and a $23.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Sanford C. Bernstein set a $24.00 target price on shares of Kura Oncology in a research note on Monday, June 15th. Jefferies Financial Group set a $24.00 target price on shares of Kura Oncology in a report on Thursday, May 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a report on Friday, July 17th.

Insider Activity at Kura Oncology

In other news, insider Mollie Leoni sold 84,929 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the transaction, the insider owned 182,345 shares of the company’s stock, valued at approximately $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

A number of large investors have recently bought and sold shares of KURA. IFP Advisors Inc lifted its holdings in shares of Kura Oncology by 115.3% in the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after buying an additional 1,284 shares during the period. Royal Bank of Canada lifted its stake in Kura Oncology by 7.6% in the fourth quarter. Royal Bank of Canada now owns 19,577 shares of the company’s stock worth $203,000 after acquiring an additional 1,375 shares during the period. Allworth Financial LP lifted its stake in Kura Oncology by 59.9% in the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after acquiring an additional 1,553 shares during the period. Focus Partners Advisor Solutions LLC grew its holdings in Kura Oncology by 7.9% during the 4th quarter. Focus Partners Advisor Solutions LLC now owns 22,889 shares of the company’s stock worth $238,000 after acquiring an additional 1,682 shares in the last quarter. Finally, ProShare Advisors LLC grew its holdings in Kura Oncology by 10.0% during the 4th quarter. ProShare Advisors LLC now owns 18,572 shares of the company’s stock worth $193,000 after acquiring an additional 1,692 shares in the last quarter.

Kura Oncology Stock Performance

Kura Oncology stock opened at $9.31 on Tuesday. The company’s 50-day moving average price is $10.24 and its 200-day moving average price is $9.27. Kura Oncology has a twelve month low of $5.45 and a twelve month high of $12.49. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09. The company has a market cap of $826.45 million, a PE ratio of -2.78 and a beta of 0.35.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. The firm had revenue of $18.27 million during the quarter, compared to the consensus estimate of $25.97 million. On average, equities research analysts forecast that Kura Oncology will post -3.45 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.